Door open for viral vector vaccines

USDA marketing approval of Syntro Corp.'s VectorVax FP-N poultry vaccine opens the way for a new generation of animal and human vaccines based on viral vector technology.
The Kansas City, Kan., company said the approval last week marks the first time that a live recombinant vaccine based on viral vectors has been approved anywhere in the world.
VectorVax protects poultry from Newcastle disease and fowlpox. It consists of the immunity-inducing genes from the Newcastle virus inserted into a fowlpox transport vector.
But the viral vector applications extend far beyond preventing infectious diseases, according to Donald Todd, president and CEO. SYNT believes that the technology is applicable to whatever products can be delivered using gene therapy systems.
The company doesn't intend to develop human